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➢To investigate the contemporary literary knowledge of the
pathogenesis of benign prostatic hyperplasia.
➢Review the drugs which are used in the treatment of benign
prostatic hyperplasia, in Republic of Macedonia, explain the
mechanisms of action, pharmacodynamics and
pharmacokinetics, their interactions, side effects if there are
and the way how to use them.
➢Review of herbal preparations which are used in the
treatment of benign prostatic hyperplasia in Republic of
Macedonia.
➢ To get information about the frequency of prescribing,
benefits and improvement of symptoms in drug treatment
in the treatment of BPH, patient satisfaction with the use of
drugs based on previously structured questionnaire,
intended for doctors - specialists in urology in :
- University Clinic for Urology in Skopje
- Clinical Hospital ‘’Acibadem Sistina ‘’ in Skopje
- Hospital ‘’8th of September ‘’ in Skopje
- Hospital in Veles
- Hospital in Kavadarci
Research objectives
Materials and methods
• PubMed
• Cochrane Library
• MEDLINE
• 14 doctors, specialists in urology.
• The first section of guetionnaire is about 
commonly prescribed medications, 
patient satisfaction while the 
consumption of drugs, duration of 
therapy.
• The second part of the questionnaire is 
designed to get information about 
herbal medicines
Results
Drug treatment therapy that is available in Rebuplic of Macedonia is
following:
➢ alpha - 1 - blockers : Terazosin, Tamsulosin, Prazosin, Doxazosin, and
Alfuzosin. These drugs reduce symptoms, increase the maximum
urinary flow and reduce the volume of residual urine . The effect of
Alpha1-blockers is seen shortly after starting therapy and proved last
few years.Patients should visit their doctor every 1 to 3 months.
➢ Inhibitors of 5 alpha – reductase: Finasteride and Dutasteride. These
drugs alleviate symptoms, increase urine flow and decrease
obstruction .The effect of these drugs, unlike of alpha - blockers
begins slowly, sometimes even after 6 months of starting treatment.
➢ 5 - alpha reductase and alpha-1 blocker reduces symptoms faster
and better than each of these two drugs separately.
➢ As an integral part in determining of the treatment for patients with
BPH is phytotherapy or the use of plant extracts. Commonly used
herbal drugs in the treatment of BPH is : Cucurbita pepo, Serenoa
repens, Pygeum africanum, Urtica diocia, Secale cereal and lycopene
rom tomatoes.
Drug treatment
Conclusions 
➢ In some patients with moderate or severe LUTS and clinical difficult
BHP, monotherapy is inadequate to control the symptoms. Due to the
high risk of progression of BPH it recommends combination therapy.
➢ According to previous literature findings, experimental works and
personal experiences of medical persons, it is proved that a
combination of 5 - alpha reductase and alpha-1 blocker reduces
symptoms faster and better than each of these two drugs separately.
➢ Herbal medicines are frequently used as a preventive therapy or in
combination with 5 - alpha reductase and alpha-1 blocker reduces.
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Introduction
➢ Prostate ( glandula prostata) is a small gland, part of the reproductive system in
males. The dimensions of the prostate show age and individual.
➢ Benign prostatic hyperplasia or even also called nodular or stromal hyperplasia Is
very common abnormality of the prostate.It is present in a significant number of
men 40 years of age, and its incidence increasing with age.
➢ Clinical manifestations occur in only about 10% of men with the disease. Because
benign prostatic hyperplasia has a bigger inclination towards the inner parts of
the prostate, the most common manifestation is obstruction of the lower urinary
tract. In addition, this include: increased frequency of urination, urgency in
urination, nocturia, urinary retention, difficulty starting urination, weak stream of
urine, a feeling of incomplete emptying of the bladder . Chronical obstruction
creates prerequisites for repeated infections of the urinary tract. Also, it can
occur and acute urinary obstruction.
➢ When BPH is diagnosed by the doctor specialist in urology, depending on the
severity of symptoms, the risk of progression and morbidity of the patient, the
next step is determining the type of treatment, monitoring, drug treatment or
surgical intervention.
According to the
information , the most often
prescribed drug is
Tamsulosin.
Most often prescribed drug at BHP
Improving the health condition of patients with 
consuming prescribed therapy 
Patient satisfaction from using drugs 
expressed as a percent
Consuming the prescribed
therapy, urine flow is
improving the fastest. This
information is obtained
because this is exactly the
response which chosen
most of doctors.
Most of the patients are
satisfied during the
consumption of drugs. It is
recognized improving of
health.
Satisfied patients by using of herbal 
preparations in percentage
As an integral part in
determining of the treatment
for patients with BPH is
phytotherapy or the use of plant
extracts, and the most of
patients are satisfied.
